[go: up one dir, main page]

CR8766A - Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso - Google Patents

Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Info

Publication number
CR8766A
CR8766A CR8766A CR8766A CR8766A CR 8766 A CR8766 A CR 8766A CR 8766 A CR8766 A CR 8766A CR 8766 A CR8766 A CR 8766A CR 8766 A CR8766 A CR 8766A
Authority
CR
Costa Rica
Prior art keywords
compounds
compositions containing
use procedures
pirazol derivatives
pirazol
Prior art date
Application number
CR8766A
Other languages
English (en)
Inventor
Emma R Parmee
Yusheng Xiong
Jian Guo
Rui Liang
Linda Brockunier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR8766A publication Critical patent/CR8766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se revelan pirazoles que tienen un grupo naftilo unido. Los compuestos son utiles para tratar la diabetes de tipo 2 y dolencias relacionadas. Tambien se incluyen composiciones farmaceuticas y procedimientos de tratamiento.
CR8766A 2004-06-04 2006-11-23 Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso CR8766A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
CR8766A true CR8766A (es) 2007-08-28

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8766A CR8766A (es) 2004-06-04 2006-11-23 Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Country Status (34)

Country Link
US (2) US7598285B2 (es)
EP (1) EP1756064B1 (es)
JP (2) JP4108739B2 (es)
CN (1) CN1964947A (es)
AR (2) AR049291A1 (es)
AT (1) ATE395338T1 (es)
AU (2) AU2005252183B2 (es)
BR (1) BRPI0511703B8 (es)
CA (1) CA2566945C (es)
CR (1) CR8766A (es)
CY (1) CY1108544T1 (es)
DE (1) DE602005006806D1 (es)
DK (1) DK1756064T3 (es)
EA (1) EA012431B1 (es)
EC (1) ECSP067062A (es)
ES (1) ES2306165T3 (es)
GE (1) GEP20094605B (es)
HR (1) HRP20080311T3 (es)
IL (1) IL179754A (es)
MA (1) MA28673B1 (es)
MX (1) MXPA06014084A (es)
MY (1) MY143599A (es)
NI (1) NI200600290A (es)
NO (1) NO339149B1 (es)
NZ (1) NZ551405A (es)
PE (1) PE20060427A1 (es)
PL (1) PL1756064T3 (es)
PT (1) PT1756064E (es)
SI (1) SI1756064T1 (es)
TN (1) TNSN06397A1 (es)
TW (1) TWI293952B (es)
UA (1) UA85884C2 (es)
WO (1) WO2005121097A2 (es)
ZA (1) ZA200609489B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1590336B1 (en) 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
DE602005021494D1 (de) 2004-07-22 2010-07-08 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
CA2614537A1 (en) 2005-07-26 2007-02-08 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2008087029A1 (en) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
KR20160052792A (ko) 2007-02-09 2016-05-12 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
US8436043B2 (en) * 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR101569227B1 (ko) 2008-03-11 2015-11-13 아스카 세이야쿠 가부시키가이샤 고체 분산체와 그 의약 조성물, 그리고 그들의 제조 방법
CA2724294A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
EP2326618B1 (en) 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Glucagon antagonists
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
US8436015B2 (en) * 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2350020B1 (en) * 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2440553B1 (en) * 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
TW201427658A (zh) * 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
SG11201901355SA (en) 2016-08-30 2019-03-28 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP7781519B2 (ja) 2017-08-22 2025-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
JPH11514651A (ja) 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP2001504490A (ja) 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法
WO1998022108A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
AU5410498A (en) 1996-12-12 1998-07-03 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
JP2001527542A (ja) 1997-04-18 2001-12-25 ジー ディ サール アンド カンパニ 心臓血管疾患の予防におけるシクロオキシゲナーゼ−２阻害剤の使用方法
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
AU755421B2 (en) 1997-12-19 2002-12-12 Amgen, Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
TR200100773T2 (tr) 1998-09-17 2001-07-23 Bristol-Myers Squibb Company Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
KR100730019B1 (ko) 1999-08-10 2007-06-20 바이엘 크롭사이언스 케이. 케이. 제초성 테트라졸리논 유도체
JP3723071B2 (ja) * 1999-11-10 2005-12-07 武田薬品工業株式会社 含窒素５員複素環化合物
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2001277056B2 (en) * 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US7514452B2 (en) 2002-02-01 2009-04-07 Dainippon Pharmaceutical Co., Ltd 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
WO2004009158A2 (en) 2002-07-19 2004-01-29 Baxter International Inc. Systems and methods for performing peritoneal dialysis
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
EP1569915A4 (en) * 2002-12-04 2007-07-11 Merck & Co Inc SPIROCYCLIC UREA, COMPOSITIONS CONTAINING THESE COMPOUNDS AND METHOD OF USE
EP1590336B1 (en) 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
BRPI0409447A (pt) * 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
AU2004238240A1 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
DE602005021494D1 (de) * 2004-07-22 2010-07-08 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
BRPI0511703A (pt) 2008-01-08
AU2008229701B2 (en) 2010-03-04
AR049291A1 (es) 2006-07-12
US7598285B2 (en) 2009-10-06
TNSN06397A1 (en) 2008-02-22
PE20060427A1 (es) 2006-06-19
JP4108739B2 (ja) 2008-06-25
DE602005006806D1 (de) 2008-06-26
MA28673B1 (fr) 2007-06-01
BRPI0511703B8 (pt) 2021-05-25
CN1964947A (zh) 2007-05-16
AR088919A2 (es) 2014-07-16
UA85884C2 (uk) 2009-03-10
EP1756064A2 (en) 2007-02-28
US20090176854A1 (en) 2009-07-09
MXPA06014084A (es) 2007-02-15
NO339149B1 (no) 2016-11-14
EP1756064B1 (en) 2008-05-14
DK1756064T3 (da) 2008-09-22
MY143599A (en) 2011-06-15
NZ551405A (en) 2009-06-26
US7799818B2 (en) 2010-09-21
WO2005121097A2 (en) 2005-12-22
IL179754A (en) 2013-12-31
AU2005252183A1 (en) 2005-12-22
HRP20080311T3 (hr) 2008-07-31
AU2005252183B2 (en) 2008-07-17
CA2566945C (en) 2010-09-21
ZA200609489B (en) 2007-10-31
EA200602196A1 (ru) 2007-06-29
NO20070073L (no) 2007-03-05
EA012431B1 (ru) 2009-10-30
ES2306165T3 (es) 2008-11-01
JP2008150388A (ja) 2008-07-03
SI1756064T1 (sl) 2008-12-31
JP2008505062A (ja) 2008-02-21
BRPI0511703B1 (pt) 2018-07-17
TWI293952B (en) 2008-03-01
JP4733153B2 (ja) 2011-07-27
AU2008229701C1 (en) 2010-07-29
PL1756064T3 (pl) 2008-11-28
PT1756064E (pt) 2008-07-22
US20050272794A1 (en) 2005-12-08
CY1108544T1 (el) 2014-04-09
GEP20094605B (en) 2009-02-10
IL179754A0 (en) 2007-05-15
TW200604179A (en) 2006-02-01
AU2008229701A1 (en) 2008-10-30
WO2005121097A3 (en) 2006-02-16
NI200600290A (es) 2007-08-07
CA2566945A1 (en) 2005-12-22
ECSP067062A (es) 2007-01-26
ATE395338T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CR10694A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
UY28342A1 (es) Nuevos compuestos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
UY28348A1 (es) Compuestos novedosos
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
GT200500307A (es) Compuestos quimicos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP088246A (es) Nuevos derivados de benzotiazolona
UY30736A1 (es) Compuestos quimicos 537
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
DOP2006000231A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
DOP2006000268A (es) Agentes antibacterianos
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos